Ischemic Heart Disease (IHD) Drugs Strategic Research Report 2024: Market to Grow by $1.1 Billion During 2023-2030, Driven by Increasing Demand for Combination Therapies
November 20, 2024 10:03 ET
|
Research and Markets
Dublin, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The "Ischemic Heart Disease (IHD) Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...
FOURIER Trial Reveals Significant Reduction in Cardiovascular Risk
March 17, 2017 10:29 ET
|
National Lipid Association
WASHINGTON, DC--(Marketwired - March 17, 2017) - The FOURIER trial lead investigators announced today that the PCSK9 inhibitor evolocumab significantly reduced the risk of cardiovascular events by...